A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 26, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NYXH SEC filings page.
Nyxoah SA (NYXH) reported $11.8M in revenue for fiscal year 2025, up 151.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 4 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Nyxoah SA's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Nyxoah SA, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Nyxoah SA had 43M shares outstanding at the end of fiscal year 2025, against 37M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Nyxoah SA scores 34/100 among other emerging companies.
Nyxoah SA spent $50.3M on research and development in fiscal year 2025, which was 45.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Nyxoah SA scores 74/100 among other emerging companies.
Nyxoah SA reported revenue of $11.8M in fiscal year 2025, against $4.7M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Nyxoah SA scores 80/100 among other emerging companies.
Nyxoah SA's operations used $81.0M of cash in fiscal year 2025, against $51.0M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Nyxoah SA scores 26/100 among other emerging companies.
Not available for Nyxoah SA, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Nyxoah SA scores -5.11, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $359.2M against total assets of $139.0M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Nyxoah SA passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.
Nyxoah SA reported a net loss of $105.7M while operations used $81.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Nyxoah SA reported an operating loss of $98.0M against $13.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Nyxoah SA generated $11.8M in revenue in fiscal year 2025. This represents an increase of 151.3% from the prior year.
Nyxoah SA's EBITDA was -$95.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
Nyxoah SA reported a net loss of $105.7M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Nyxoah SA earned -$2.77 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Cash & Balance Sheet
Nyxoah SA recorded an outflow of $81.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Nyxoah SA held $35.2M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Margins & Returns
Nyxoah SA's gross margin was 63.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 2.5 percentage points from the prior year.
Nyxoah SA's ROE was -183.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 131.1 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Nyxoah SA invested $50.3M in research and development in fiscal year 2025. This represents an increase of 41.5% from the prior year.
Nyxoah SA invested $945K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 21.7% from the prior year.
Not reported for fiscal year 2025.
NYXH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F |
|---|---|---|---|---|---|---|---|
| Revenue | $11.8M+151.3% | $4.7M-2.7% | $4.8M+45.8% | $3.3M+242.1% | $964K+1042.7% | $84K | N/A |
| Cost of Revenue | $4.3M+169.9% | $1.6M-12.3% | $1.8M+48.9% | $1.2M+258.7% | $343K+834.7% | $37K | N/A |
| Gross Profit | $7.4M+141.6% | $3.1M+3.2% | $3.0M+43.9% | $2.1M+233.0% | $621K+1202.7% | $48K | N/A |
| R&D Expenses | $50.3M+41.5% | $35.5M+20.5% | $29.5M+73.7% | $17.0M+21.5% | $14.0M+389.0% | $2.9M | N/A |
| Operating Income | -$98.0Mn/m | -$60.9Mn/m | -$49.9Mn/m | -$34.8Mn/m | -$29.7Mn/m | -$13.7M | N/A |
| EBITDA | -$95.3Mn/m | -$59.1Mn/m | -$48.3M | N/A | N/A | N/A | N/A |
| Interest Expense | $13.5M+157.6% | $5.2M+27.2% | $4.1M-10.7% | $4.6M+97.1% | $2.3M+93.7% | $1.2M | N/A |
| Income Tax | $1.2M-59.2% | $2.9Mn/m | -$1.6M-227.8% | $1.3M-62.9% | $3.4M+2865.4% | $114K | N/A |
| Net Income | -$105.7Mn/m | -$61.3Mn/m | -$47.8Mn/m | -$33.4Mn/m | -$31.3Mn/m | -$15.0M | N/A |
| EPS (Basic) | -$2.77n/m | -$1.87n/m | -$1.71n/m | -$1.29n/m | -$1.31n/m | -$0.83 | N/A |
| EPS (Diluted) | -$2.77n/m | -$1.87n/m | -$1.71n/m | -$1.29n/m | -$1.31n/m | -$0.83 | N/A |
Not reported in any period shown, so not listed: SG&A Expenses, Diluted Shares (Avg).
NYXH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F |
|---|---|---|---|---|---|---|---|
| Total Assets | $139.0M-15.2% | $164.0M+19.4% | $137.3M-12.1% | $156.3M-19.2% | $193.3M | N/A | N/A |
| Current Assets | $71.8M-29.2% | $101.5M+34.3% | $75.6M-29.5% | $107.3M-32.3% | $158.5M | N/A | N/A |
| Cash & Equivalents | $35.2M-0.5% | $35.4M+48.0% | $23.9M+24.9% | $19.1M-87.5% | $153.4M+35.9% | $112.9M+1617.3% | $6.6M |
| Inventory | $5.5M+12.0% | $4.9M+33.1% | $3.7M+288.6% | $944K+140.9% | $392K | N/A | N/A |
| Total Liabilities | $81.4M+74.1% | $46.7M+61.7% | $28.9M+5.0% | $27.5M+9.6% | $25.1M | N/A | N/A |
| Current Liabilities | $57.5M+157.8% | $22.3M+39.5% | $16.0M+0.1% | $16.0M+21.8% | $13.1M | N/A | N/A |
| Non-Current Liabilities | $23.9M-2.2% | $24.5M+89.1% | $12.9M+11.6% | $11.6M-3.7% | $12.0M | N/A | N/A |
| Total Equity | $57.7M-50.8% | $117.2M+8.1% | $108.4M-15.8% | $128.7M-23.5% | $168.2M | N/A | N/A |
| Retained Earnings | -$359.2Mn/m | -$225.4Mn/m | -$177.9Mn/m | -$126.5Mn/m | -$98.7M | N/A | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.
NYXH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$81.0Mn/m | -$51.0Mn/m | -$49.5Mn/m | -$30.8Mn/m | -$28.7Mn/m | -$8.4Mn/m | -$6.7M |
| Depreciation & Amortization | $2.6M+45.9% | $1.8M+17.3% | $1.5M | N/A | N/A | N/A | N/A |
| Capital Expenditures | $945K-21.7% | $1.2M-56.4% | $2.8M+191.8% | $948K-43.0% | $1.7M+141.9% | $687K+1100.4% | $57K |
| Free Cash Flow | -$81.9Mn/m | -$52.2Mn/m | -$52.3Mn/m | -$31.7Mn/m | -$30.3Mn/m | -$9.1Mn/m | -$6.7M |
| Investing Cash Flow | $33.3Mn/m | -$16.9M-147.7% | $35.4Mn/m | -$96.2Mn/m | -$13.4Mn/m | -$13.1Mn/m | -$6.5M |
| Financing Cash Flow | $44.7M-44.2% | $80.2M+329.8% | $18.6Mn/m | -$1.1M-101.2% | $86.6M-32.0% | $127.2M+16088.3% | $786K |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
NYXH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F |
|---|---|---|---|---|---|---|---|
| Gross Margin | 63.1%-2.5pp | 65.7%+3.8pp | 61.9%-0.8pp | 62.7%-1.7pp | 64.4%+7.9pp | 56.5% | N/A |
| Operating Margin | -833.2% | -1300.8% | -1037.3% | -1053.8% | -3080.0% | -16266.7% | N/A |
| Net Margin | -899.1% | -1310.2% | -993.8% | -1012.5% | -3241.7% | -17746.4% | N/A |
| Return on Equity | -183.4%-131.1pp | -52.3%-8.2pp | -44.1%-18.1pp | -25.9%-7.4pp | -18.6% | N/A | N/A |
| Return on Assets | -76.0%-38.6pp | -37.4%-2.6pp | -34.8%-13.4pp | -21.4%-5.2pp | -16.2% | N/A | N/A |
| Current Ratio | 1.25-3.3x | 4.56-0.2x | 4.73-2.0x | 6.72-5.4x | 12.10 | N/A | N/A |
| Liabilities-to-Equity | 1.41+1.0x | 0.40+0.1x | 0.27+0.1x | 0.21+0.1x | 0.15 | N/A | N/A |
| Asset Turnover | 0.08+0.1x | 0.030.0x | 0.040.0x | 0.020.0x | 0.01 | N/A | N/A |
| FCF Margin | -696.4% | -1114.6% | -1087.4% | -961.2% | -3146.1% | -10762.3% | N/A |
Not reported in any period shown, so not listed: Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Nyxoah SA NYXH | FY2025 | $11.8M | -$105.7M | N/A | $85.0M | 54/100 |
| OraSure Technologies Inc OSUR | FY2025 | $115.0M | -$68.7M | -59.8% | $284.8M | 46/100 |
| InfuSystem Holdings, Inc. INFU | FY2025 | $143.4M | $6.6M | 4.6% | $277.6M | 59/100 |
| KORU Medical Systems, Inc. KRMD | FY2025 | $41.1M | -$2.6M | -6.4% | $145.6M | 67/100 |
| Anteris Technologies Global Corp. AVR | FY2025 | $1.9M | -$94.1M | N/A | $572.1M | 22/100 |
Where Nyxoah SA Ranks
Frequently Asked Questions
What is Nyxoah SA's annual revenue?
Nyxoah SA (NYXH) reported $11.8M in total revenue for fiscal year 2025. This represents a 151.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Nyxoah SA's revenue growing?
Nyxoah SA (NYXH) revenue grew by 151.3% year-over-year, from $4.7M to $11.8M in fiscal year 2025.
Is Nyxoah SA profitable?
No, Nyxoah SA (NYXH) reported a net loss of $105.7M in fiscal year 2025.
What is Nyxoah SA's EBITDA?
Nyxoah SA (NYXH) had EBITDA of -$95.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Nyxoah SA's gross margin?
Nyxoah SA (NYXH) had a gross margin of 63.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Nyxoah SA's return on equity (ROE)?
Nyxoah SA (NYXH) has a return on equity of -183.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Nyxoah SA's free cash flow?
Nyxoah SA (NYXH) recorded an outflow of $81.9M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nyxoah SA's operating cash flow?
Nyxoah SA (NYXH) recorded an outflow of $81.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Nyxoah SA's total assets?
Nyxoah SA (NYXH) had $139.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Nyxoah SA's capital expenditures?
Nyxoah SA (NYXH) invested $945K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Nyxoah SA spend on research and development?
Nyxoah SA (NYXH) invested $50.3M in research and development during fiscal year 2025.
What is Nyxoah SA's current ratio?
Nyxoah SA (NYXH) had a current ratio of 1.25 as of fiscal year 2025, which is considered adequate.
What is Nyxoah SA's liabilities-to-equity ratio?
Nyxoah SA (NYXH) had a liabilities-to-equity ratio of 1.41 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Nyxoah SA's return on assets (ROA)?
Nyxoah SA (NYXH) had a return on assets of -76.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nyxoah SA's P/E ratio?
Nyxoah SA (NYXH) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $85.0M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Nyxoah SA's price-to-sales ratio?
Nyxoah SA (NYXH) trades at 7.2x sales, its market capitalization divided by $11.8M revenue, FY2025. The market capitalization is $85.0M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Nyxoah SA's Altman Z-Score?
Nyxoah SA (NYXH) has an Altman Z-Score of -5.11, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Nyxoah SA's Piotroski F-Score?
Nyxoah SA (NYXH) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nyxoah SA's earnings high quality?
Nyxoah SA (NYXH) reported a net loss of $105.7M while operations used $81.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Nyxoah SA cover its interest payments?
Nyxoah SA (NYXH) reported an operating loss of $98.0M against $13.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Nyxoah SA?
Nyxoah SA (NYXH) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Nyxoah SA it averages the 4 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.